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Abstract
Background: The currently used anthelmintic drugs, in single oral application, have low efficacy against Trichuris trichiura
infection, and hence novel anthelmintic drugs are needed. Nitazoxanide has been suggested as potential drug candidate.
Methodology: The efficacy and safety of a single oral dose of nitazoxanide (1,000 mg), or albendazole (400 mg), and a
nitazoxanide-albendazole combination (1,000 mg–400 mg), with each drug administered separately on two consecutive
days, were assessed in a double-blind, randomized, placebo-controlled trial in two schools on Pemba, Tanzania. Cure and
egg reduction rates were calculated by per-protocol analysis and by available case analysis. Adverse events were assessed
and graded before treatment and four times after treatment.
Principal Findings: Complete data for the per-protocol analysis were available from 533 T. trichiura-positive children. Cure
rates against T. trichiura were low regardless of the treatment (nitazoxanide-albendazole, 16.0%; albendazole, 14.5%; and
nitazoxanide, 6.6%). Egg reduction rates were 54.9% for the nitazoxanide-albendazole combination, 45.6% for single
albendazole, and 13.4% for single nitazoxanide. Similar cure and egg reduction rates were calculated using the available
case analysis. Children receiving nitazoxanide had significantly more adverse events compared to placebo recipients. Most
of the adverse events were mild and had resolved within 24 hours posttreatment.
Conclusions/Significance: Nitazoxanide shows no effect on T. trichiura infection. The low efficacy of albendazole against T.
trichiura in the current setting characterized by high anthelmintic drug pressure is confirmed. There is a pressing need to
develop new anthelmintics against trichuriasis.
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Introduction
Infections with the soil-transmitted helminths, Ascaris lumbri-
coides, Trichuris trichiura, and the two hookworm species Ancylostoma
duodenale and Necator americanus, are the most common infections of
humans, causing an estimated global burden of 39 million
disability-adjusted life years lost (DALYs) [1–3]. Globally more
than 5 billion people are at risk and at least 1 billion people are
currently infected with one or several of these nematodes [1,3,4].
On Pemba, soil-transmitted helminth infections remain of
considerable public health importance with particularly high
prevalences observed for T. trichiura and hookworm [5].
Preventive chemotherapy targeting at-risk communities (i.e.,
school-aged children) is in place in many countries. These
programs aim at morbidity control, and hence intensity of
infection is kept below a threshold of disease [6]. The two
benzimidazoles, albendazole and mebendazole, as well as pyrantel
pamoate and levamisole are recommended drugs against infec-
tions with soil-transmitted helminths [7,8]. These drugs have been
widely used as they were developed and put on the market
between 1966 (pyrantel pamoate) and 1980 (albendazole) [9]. The
four drugs exhibit distinct differences in their therapeutic profile,
with the exception of considerably high efficacy of all drugs against
A. lumbricoides. For the treatment of hookworm infection, only
albendazole achieves satisfactory cure rates when administered as
a single oral dose. Of particular concern is the situation for T.
trichiura; single doses of mebendazole show the highest cure rates,
but these are usually low or only moderate (,50%) [10]. The
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pressing need for developing new anthelmintic drugs, particularly
for T. trichiura, cannot be emphasized enough. In addition, the
therapeutically useful life span of these drugs is endangered should
resistance develop and start to spread [11–13].
The antiprotozoal drug nitazoxanide, which is marketed for the
treatment of intestinal parasitic infections (i.e., Cryptosporidium
parvum and Giardia intestinalis) has been reported to also have
trichuricidal properties [14,15]. Silbereisen and colleagues recently
showed that nitazoxanide is highly active against Trichuris muris in
vitro [16]. In clinical trials high cure rates were reported against T.
trichiura as well as A. lumbricoides and hookworm, following multiple
doses (200 mg for children aged below 12 years and 500 mg for
patients aged 12 years and above, twice daily for 3 days) of
nitazoxanide [17–19]. Hence, nitazoxanide has been listed as a
potential drug candidate for human-soil transmitted helminthiasis
and further research was suggested [20].
We report the findings of a randomized, double-blind, placebo-
controlled trial, which specifically assessed the efficacy and safety
of nitazoxanide given as a single dose (1,000 mg) in the treatment
of T. trichiura in school-aged children on Pemba, Tanzania. The
standard treatment with albendazole (400 mg) served as a
benchmark. In addition, one group of children was given
nitazoxanide (1,000 mg) on the first day and albendazole
(400 mg) on the following day, in order to evaluate if an enhanced
efficacy would be observed following this combination chemo-
therapy. A fourth group of children received placebo (the
treatment groups are summarized in Figure 1). Since A. lumbricoides
and hookworm coexist in the current setting, outcomes on these
nematodes are also reported.
Methods
Ethics Statement
Ethical clearance was obtained from the ethics committee of
Basel, Switzerland (EKBB, reference no. 225/10) and from the
Ministry of Health and Social Welfare in Zanzibar (ZAMREC,
reference no. 0001/010). The study is registered at Current
Controlled Trials (ISRCTN08336605). Written informed consent
was acquired from the children’s parents or legal guardians to
participate in this trial. Children assented orally. It was empha-
sized that study participation would be voluntary and withdrawal
possible at any time.
Study Setting
Our trial was carried out in June and July 2011 on Pemba, one
of the major islands in the Zanzibar archipelago, which belongs to
Tanzania. The schools of Wawi (geographical coordinates;
5u159220S latitude, 39u479280E longitude) and Al-Sadik
(5u159420S, 39u489250E), both located less than 10 km from
Chake Chake, the main town of Pemba (5u149450S, 39u459000E,
,22,000 inhabitants), were selected. In the school year 2010/
2011, a total of 1,100 children were registered in Wawi and 437 in
Al-Sadik. Both schools were easily accessible by car from the
Public Health Laboratory–Ivo de Carneri (PHL–IdC) in Chake
Chake.
Sample Size Calculation
To determine the sample size, we assumed a cure rate of 28%
for single oral albendazole against T. trichiura based on data from a
meta-analysis [21]. The efficacy of single oral nitazoxanide against
T. trichiura is not known. Therefore we assumed that it would be at
least similar to that of albendazole (20–30%). Moreover, we
hypothesized that an albendazole-nitazoxanide combination
would achieve a considerably higher cure rate (50%). Monte
Carlo simulations (imperfect test with a sensitivity of 90%)
computed a sample size of 95 T. trichiura-infected individuals in
each arm to detect a difference of single medication treatments
versus both, the placebo group and the albendazole-nitazoxanide
group at a significance level of 5% with 80% power. Allowing for
drop outs and assuming an overall T. trichiura prevalence of 80%,
we targeted approximately 125 children per treatment arm for the
baseline screening.
Study Flow and Procedures
Before the onset of the study, the headmasters of Wawi and Al-
Sadik were asked for permission to carry out the trial at their
schools. The parents of the children were invited to the schools, so
that they could be explained the purpose and procedures of the
study, including potential risks and benefits. Questions could be
asked in a discussion round and clarification was given to parents.
At the first day of enrolment, all children attending standards
one to five received an empty stool container together with a
consent form; both labeled with unique identification numbers
(ID). After recording their name, sex, age, and school grade,
children were invited to return the container with a fresh sample of
the next morning stool together with the signed consent form.
Filled stool containers and signed consent forms were collected
from the children and a new empty container was handed out for
collection of a second stool sample on the following day.
All children who returned a signed informed consent and had
two stool samples were assigned to one of the four treatment
groups, regardless of their helminths infection status. Before drug
administration, all children were examined by a physician.
Exclusion criteria were: (i) presence of any abnormal medical
condition, judged by the study physician; (ii) history of acute or
severe chronic disease (cancer, diabetes, chronic heart, liver, or
renal disease); and (iii) recent use of anthelmintic drugs (within past
4 weeks). Additionally, the weight and height of all children were
measured and if there was any indication of fever, axillary
temperature was taken using a digital thermometer.
Author Summary
More than 5 billion people are at risk of infection with one
of the three most common intestinal worms, the round-
worm Ascaris lumbricoides, the whipworm Trichuris tri-
chiura, and two different kinds of hookworms. The global
strategy to control these intestinal worm infections is
through the regular administration of deworming drugs to
school-aged children (albendazole, 400 mg; mebendazole,
500 mg). However, especially against T. trichiura, a low
treatment response is observed with single doses of both
drugs. We tested the antiprotozoal drug nitazoxanide,
which had shown promising trichuricidal properties in in
vitro experiments. A randomized controlled trial was
carried out on the island of Pemba in Tanzania. Four
treatment arms were included: (i) single albendazole
(400 mg), (ii) single nitazoxanide (1,000 mg), (iii) nitazox-
anide-albendazole combination (1,000 mg–400 mg) with
each drug given separately on two consecutive days, and
(iv) placebo. Children were asked for adverse events at
several time points after treatment. Nitazoxanide showed
no ability to cure T. trichiura-infected children and caused
significantly more mild adverse events than placebo.
Albendazole and the nitazoxanide-albendazole combina-
tion showed only a minimal effect against T. trichiura. Our
results emphasize the urgent need to develop new, safe,
and effective anthelmintic drugs against T. trichiura.
Nitazoxanide and Albendazole against Trichuriasis
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Three weeks posttreatment, children were asked again for two
stool samples collected over consecutive days to determine the
efficacy of the different treatments. At the end of the study, all
children who were still infected with soil-transmitted helminths
were offered a dose of albendazole (400 mg) following national
guidelines [7,8].
Randomization, Treatment, and Adverse Events
An independent statistician created a randomization code
assigning to each ID a number from 1–4, representing the four
treatment arms: (i) nitazoxanide (1,000 mg) plus albendazole
(400 mg); (ii) nitazoxanide-matching placebo plus albendazole
(400 mg); (iii) nitazoxanide (1,000 mg) plus albendazole-matching
placebo; and (iv) two placebos. For blinding purposes, the tablets
were packed before treatment into small plastic bags, labeled with
the unique IDs. Nitazoxanide (AliniaH) and albendazole (ZentelH)
tablets were the products of Romark and GlaxoSmithKline,
respectively. Placebos were produced at the Department of
Pharmaceutical Sciences, University of Basel by one of the
authors (R.A.). During the trial all drugs were stored at room
temperature, not exceeding 25uC. Since interactions between
nitazoxanide and albendazole have not been studied before, the
two drugs were administered on two consecutive days. Hence, on
the first day of treatment, children received two tablets of
nitazoxanide (500 mg each) or two nitazoxanide-matching place-
bos. On the second day, children received one tablet of
albendazole (400 mg) or an albendazole-matching placebo. Since
the trial was double-blinded, neither the child, nor the person
giving the treatment knew to which treatment arm the child was
allocated to.
Before treatment, children were asked if they suffer from any
adverse events. Drugs were then administered with a cup of water
and each child received a small snack. Three hours after
treatment, adverse events were actively assessed by interviewing
Figure 1. Flow diagram illustrating the compliance in the randomized controlled trial. Flow diagram of the randomized, placebo-
controlled trial assessing the efficacy of albendazole, nitazoxanide, and albendazole combined with nitazoxanide, administered separately on two
consecutive days, in the treatment of Trichuris trichiura infections.
doi:10.1371/journal.pntd.0001685.g001
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each child. On the following day, before receiving the second
treatment, adverse events were investigated again. The same
procedures were repeated 3 and 24 hours after the second
treatment.
Parasitological Analysis
Stool samples were transferred to PHL–IdC. Duplicate Kato-
Katz thick smears, using 41.7 mg templates, were prepared from
each stool sample [22]. Kato-Katz thick smears were examined
under a microscope by experienced laboratory technicians within
20–40 min after preparation, as recommended to avoid over
clearing of hookworm eggs [23]. All hookworm eggs were counted.
Subsequently, the slides were re-examined for T. trichiura and A.
lumbricoides, with parasite eggs counted and recorded separately.
To ensure high quality of the diagnosis, 10% of the slides, selected
at random, were re-examined. In cases of discordant results, slides
were read a third time and results discussed until agreement was
reached.
Statistical Analysis
Parasitological data and reported adverse events were double
entered into an Excel spreadsheet and cross-checked. In case of
discrepancy, the original files were consulted to correct the data
entry. All statistical analyses were performed with Stata 10.1
software (StataCorp).
Cure rates were calculated as the proportion of egg-positive
children at baseline, who became egg-negative after treatment.
Egg counts from the four Kato-Katz thick smears were added up
for each species and multiplied by a factor 6 and expressed as eggs
per gram of stool (EPG). Infection intensity was classified using
pre-defined cut-offs by the World Health Organization (WHO; T.
trichiura light, 1–999 EPG; moderate, 1,000–9,999; and heavy,
$10,000) [24]. Differences among treatment arms concerning
cure rates and observed adverse events were analyzed with logistic
regressions.
Geometric mean egg counts were calculated for the different
treatment arms before and after drug intervention to calculate the
respective egg reduction rates (ERR). We also calculated the
average dose (mg/kg) of each drug that the children received per
treatment arm and analyzed with a logistic regression if the dose of
treatment had an influence on the cure rates.
We used two different types of analyses: (i) per-protocol analysis,
including only those children who had complete data records
(quadruplicate Kato-Katz results before and after treatment and
being treated); and (ii) available case analysis (which is sometimes
erroneously referred to as an intention-to-treat analysis [25]) based
on the treatment intent, hence analyzing data from all individuals
who were assigned to one of the four treatment arms and had
primary outcome data. A greater emphasis is given in our
manuscript on the per-protocol analysis (available case results
summarized in Table S1) since a bias might have been introduced
in the available case analysis given that children absent on the first
treatment day (nitazoxanide) were shifted to a later starting
treatment period, while this was not possible for children missing
the second treatment day (albendazole).
Results
Adherence
From the 928 children invited to participate in the study, 172
refused to participate or did not return a signed consent form.
Another 47 children failed to provide two stool samples and from
seven children the IDs on the stool samples were lost and hence
they had to be excluded from the trial. One child received
anthelmintic treatment less than 4 weeks before the onset of our
trial and was therefore excluded. The remaining 701 children (549
from Wawi and 152 from Al-Sadik) were randomly assigned to
one of the four treatment arms independently of their parasito-
logical status. Of these, 124 were T. trichiura-negative and therefore
excluded from the final analysis (Figure 1). Fifteen children missed
the first treatment, and 14 children were absent on the second day
of treatment. At follow-up, 13 children provided no or only a
single stool sample and two children were excluded due to other
reasons. In total 44 T. trichiura-infected children were lost during
treatment and follow-up. Hence, 533 children were included in the
per-protocol analysis. The loss of participants was distributed
equally over the different treatment arms; the double placebo
group was characterized by loss of the most participants (n = 14).
Of the 29 participants not receiving treatment, all 14 who missed
the second treatment provided primary end point data and could
therefore be followed up; hence 547 children were included in the
available case analysis.
Baseline Characteristics
Most of the 701 children subjected to multiple Kato-Katz thick
smears readings were diagnosed positive for T. trichiura (n = 577,
82%). Infections were mainly of light intensity (94%) and only one
heavy T. trichiura infection was identified. Prevalence of hookworm
and A. lumbricoides were 7% and 5%, respectively, and most of
these infections were of light intensity. An infection with all three
helminth species was diagnosed in 11 children (1.5%). The mean
age of the 701 children was 10 years (range 7–15 years). Mean age,
weight, and height were comparable in all four treatment arms
(Table 1). There was a similar number of boys (n = 348) and girls
(n = 353) participating in the study.
Efficacy against T. trichiura
Only very low cure rates were observed regardless of whether
the sequentially administered nitazoxanide-albendazole combina-
tion, albendazole, or nitazoxanide were administered. In more
detail, using the per-protocol analysis, nitazoxanide combined with
albendazole achieved a cure rate of 16.0% (95% confidence
interval (CI), 9.7–22.4%), whereas single doses of albendazole or
nitazoxanide resulted in cure rates of 14.5% (95% CI, 8.4–20.6%),
and 6.6% (95% CI, 2.4–10.8%), respectively. Children receiving
placebo showed an apparent cure rate of 8.9% (95% CI, 4.0–
13.8%) (Table 2). Similar results were observed using the available
case analysis (Table S1). Comparing the treatment outcomes using
a logistic regression revealed that albendazole had a significant
effect on infections with T. trichiura (odds ratio (OR), 0.47; 95% CI,
0.27–0.81; p = 0.007) while nitazoxanide showed no effect (OR,
1.04; 95% CI, 0.61–1.78; p = 0.89). There was some indication of
an interaction between the two drugs (OR, 0.64; 95% CI, 0.21–
1.98), however, this result was not significant (p = 0.44).
The ERR for T. trichiura was 54.9% (bootstrap 95% CI, 37.7–
67.9%) for the nitazoxanide-albendazole combination, 45.6%
(95% CI, 25.9–61.0%) for albendazole alone, 13.4% (95% CI,
0.0–33.7%) for nitazoxanide alone, and 17.6% (95% CI, 0.0–
36.7%) for the placebo-controlled treatment arm (Table 2). Large
confidence intervals indicate a high variance in ERRs. Therefore
the only significant difference between the treatment arms (defined
by non-overlapping bootstrap CI), was found between nitazox-
anide-albendazole compared to the nitazoxanide monotherapy
treatment group and the placebo-controlled treatment arm.
However, even though CIs are overlapping, there seems to be a
trend that albendazole alone resulted in higher ERRs.
The amount of milligrams of drug administered per kilogram of
body weight ranged from 22.7 to 64.9 mg/kg for nitazoxanide and
Nitazoxanide and Albendazole against Trichuriasis
www.plosntds.org 4 June 2012 | Volume 6 | Issue 6 | e1685
from 7.7 to 27.2 mg/kg for albendazole (Table 2). Logistic
regression revealed no statistically significant association between
body weight and cure rates between the different treatment arms
which received an active drug.
Efficacy against Other Soil-Transmitted Helminths
Less than 10% of the children were infected with hookworm
(n= 48; 7%) and A. lumbricoides (n = 31; 4%). Albendazole was
highly efficacious against both parasites with cure rates of 100%
against A. lumbricoides and 81.8% against hookworm (95% CI,
54.6–100%). Nitazoxanide showed moderate efficacy against those
two nematode species with cure rates of 66.7% (95% CI, 35.4–
98.0%) against hookworm and 62.5% (95% CI 19.2–100.0%)
against A. lumbricoides (Table 2). These data, however, lacked
statistical significance. Of note, placebo had an apparent cure rate
against hookworm infection of 55.6%.
Adverse Events
In total, 678 of the treated children answered a standardized
questionnaire pertaining to adverse events. However, not all of
these children responded at each of the five follow-up time points
(Table 3). Before treatment, 28 (4.1%) children reported minor
symptoms (e.g., headache and abdominal pain). After treatment
(both first and second round of treatment) a total of 244 children
complained at least once about minor adverse events at one of the
four follow-up examinations (3 and 24 hours after each treatment).
Only one child had moderate adverse events, namely headache
24 hours after receiving nitazoxanide. This child was treated with
paracetamol and the headache resolved within 3 hours. In total
307 adverse events were reported after starting the treatment
regimen. Abdominal cramps and headache were the most frequent
ones (165 times (53.7%) and 69 times (22.5%), respectively) (Table
S2). Other reported adverse events were nausea (6.8%), vertigo
(5.5%), diarrhea (4.6%), fever (3.6%), allergic reaction (1.6%),
vomiting (1.3%), and fatigue (0.3%).
Three hours after the first treatment, minor adverse events were
reported by 101 (14.9%) participants. Children who received
placebo reported significantly more about minor adverse events
compared to the pretreatment situation (OR, 2.97; 95% CI, 1.50–
6.21) (Table 3). Children who were given single nitazoxanide had
significantly more adverse events 3 hours after treatment com-
pared to the placebo recipients at the same time point (OR, 2.02;
95% CI, 1.28–3.24). On the next day (24 hours after the first
treatment) 56 (8.3%) children reported adverse events. Participants
receiving nitazoxanide still had significantly higher odds of
reporting adverse events (OR, 2.49; 95% CI, 1.38–4.50). Three
hours after the second treatment, children treated with albenda-
zole did not report significantly more adverse events than placebo
recipients (OR, 1.47; 95% CI, 0.59–3.70). At this time point,
nitazoxanide was no longer associated with significantly more
adverse events than placebo recipients (OR, 2.04; 95% CI, 0.85–
Table 1. Baseline characteristics of school-aged children included in the trial.
Characteristic Overall Nitazoxanide+albendazole Only albendazole Only nitazoxanide Only placebo
N 701 165 177 180 179
Age mean (6SD), years 9.7 (1.6) 9.7 (1.6) 9.8 (1.7) 9.4 (1.6) 9.9 (1.6)
No. of boys/girls 348/353 82/83 85/92 94/86 87/92
No. of participants Wawi/Al Sadique 549/152 127/38 142/35 139/41 141/38
Weight mean (6SD), kga 26 (5.6) 26 (5.6) 26 (5.9) 26 (5.3) 26 (5.4)
Height mean (6SD), cmb 130 (9.2) 130 (9.4) 130 (9.3) 129 (9.3) 130 (8.8)
Infected with T. trichiura
No. infected children (%) 577 (82.3) 142 (86.1) 142 (80.2) 144 (80.0) 149 (83.2)
Geometric mean, EPG 153 147 162 148 156
Infection intensity, no (%) of infected
children
Light (1–999 EPG) 541 (93.7) 133 (93.0) 131 (92.3) 137 (95.1) 140 (94.6)
Moderate (1,000–9,999 EPG) 35 (6.1) 10 (7.0) 10 (7.0) 7 (4.9) 8 (5.4)
Heavy ($10,000 EPG) 1 (0.2) 1 (0.7)
Infected with hookworm
No. infected children (%) 48 (6.8) 15 (9.0) 11 (6.2) 13 (7.2) 9 (5.0)
Geometric mean EPG* 36 35 37 39 35
Infected with A. lumbricoides
No. infected children (%) 31 (4.4) 6 (3.6) 9 (5.1) 8 (4.4) 8 (4.5)
Geometric mean EPG 507 686 207 435 1,297
Infection intensity, no (%) of infected
participants
Light (1–4,999 EPG) 29 (93.6) 5 (83.3) 9 (100) 8 (100) 7 (87.5)
Moderate (5,000–49,000 EPG) 2 (6.6) 1 (6.7) 0 0 1 (12.5)
a684 datasets.
b683 datasets.
*all infections with hookworms were classified as light.
doi:10.1371/journal.pntd.0001685.t001
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4.91) and both drugs combined (treatment group 1) showed no
cumulative effect regarding adverse events (OR, 0.67; 95% CI,
0.21–2.18). Twenty-four hours after the second treatment adverse
events were resolved. Logistic regression revealed ORs of 0.77
(95% CI 0.35–1.71) for albendazole, 0.76 (95% CI 0.35–1.69) for
nitazoxanide, and 1.40 (95% CI 0.44–4.41) for the sequentially
administered nitazoxanide-albendazole combination.
Discussion
Following up on the promising trichuricidal properties observed
in in vitro studies [16], we carried out the first randomized, double-
blind, placebo-controlled trial administering nitazoxanide as a
single dose of 1,000 mg to T. trichiura-infected school-aged children
in a highly endemic area in Pemba. In addition, since combination
chemotherapy is being advocated in many therapeutic areas, as it
enhances efficacy and lowers the risk of resistance development
[26], one group of children was treated with a nitazoxanide-
albendazole combination which was administered over two
consecutive days.
A high single dose of nitazoxanide (1,000 mg) showed no
therapeutic effect against T. trichiura. This result is in contrast to
previous studies, which reported high cure rates when the drug
was administered as multiple dose treatment regimen (6 times
200 mg or 500 mg) to T. trichiura-infected patients [17–19]. It is
plausible that pharmacokinetic properties of ‘‘multiple doses a
day’’ nitazoxanide are superior to ‘‘once a day’’ nitazoxanide in
that it achieves a longer half life. However, since the global
strategy targeting neglected tropical diseases advocates preventive
chemotherapy (i.e., regular deworming with single oral doses),
multiple dosing is currently not recommended, as it poses
operational and financial challenges [27]. A rigorous diagnostic
approach as performed in this study (two times duplicate Kato-
Katz thick smears before and after treatment) can lead to lower
observed cure rates, since, especially light infections, are more
likely to be detected [28]. Nevertheless, two of the above
mentioned studies which found high cure rates and ERRs for
nitazoxanide against T. trichiura infections also collected several
stool samples after treatment, and hence pursued a thorough
diagnostic approach. Diagnosis, therefore, does not seem to be the
main reason for the contradictory results.
The standard treatment albendazole revealed a very low cure
rate against T. trichiura when given at a single dose of 400 mg,
which is in agreement with the results of several previous studies
[21,29,30]. It is interesting to note that the ERR following
albendazole treatment was still moderate (73%) in the same setting
12 years ago, but was similarly low as the ERR obtained in this
trial, in a study conducted by Knopp et al. in 2009 in neighboring
Unguja, Zanzibar [29,30]. This might be an indicator of tolerance
Table 2. Effect of albendazole, nitazoxanide, sequentially administered albendazole-nitazoxanide combination, and placebo
against soil-transmitted helminths.
Characteristic Nitazoxanide+albendazole Only albendazole Only nitazoxanide Only placebo
Trichuris trichiura
No. of infected children 131 131 136 135
No. of children not cured after treatment 110 112 127 123
Cure rate % (95% CI) 16.0 14.5 6.6 8.9
(9.7–22.4) (8.4–20.6) (2.4–10.8) (4.0–13.8)
Geometric mean, EPG
Before treatment 152 164 145 154
After treatment 69 89 125 127
Egg reduction rate % (95% CI*) 54.9 45.6 13.4 17.6
(37.7–67.9) (25.9–61.0) (0.0–33.7) (0.0–36.7)
Hookworm
No. of infected children 14 11 12 9
No. of children not cured after treatment 2 2 4 4
Cure rate % (95% CI) 85.7 81.8 66.7 55.6
(64.7–100.0) (54.6–100.0) (35.4–98.0) (15.0–96.1)
Ascaris lumbricoides
No. of infected children 5 9 8 7
No. of children not cured after treatment 0 0 3 7
Cure rate % (95% CI) 100.0 100.0 62.5 0.0
(19.2–100.0)
Range of actual treatment dose (mg/kg)
Nitazoxanide mean (min, max) 38.2 - 38.9 -
(22.7–64.9) (23.9–54.1)
Albendazole mean (min, max) 15.3 15.0 - -
(9.1–26.0) (7.7–27.2)
Effect of different treatments calculated with the per-protocol analysis.
*95% CI of egg reduction rates were calculated using bootstrap resampling.
doi:10.1371/journal.pntd.0001685.t002
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or resistance development to albendazole against T. trichiura. Of
note, Levecke et al. [31] recently showed that ERRs can differ
strongly between individual settings and that albendazole has
higher ERRs in settings with low infection intensities. Our trial
could not confirm this hypothesis since albendazole achieved only
a low ERR in children characterized by low infection intensities.
The combination of albendazole and nitazoxanide had slightly,
though not significantly higher cure rates and ERRs than
albendazole alone. Since drug interactions have not been
evaluated for this combination, drugs were administered on
subsequent days. One disadvantage of spacing the drug is that
synergistic effects might be missed. On the other hand, a recent
study which examined the effect of a simultaneous nitazoxanide-
albendazole combination against adult T. muris in vitro detected an
antagonistic effect [32].
Only a few children were (co)-infected with hookworm and/or
A. lumbricoides. Nonetheless, these data illustrate that the standard
treatment albendazole has a high efficacy against these parasites.
The good activity against these two helminths and low efficacy
against T. trichiura is also supported by the baseline prevalences (T.
trichiura (82.2%), hookworm (6.8%), and A. lumbricoides (4.6%))
observed in the current trial. The settings where the study was
conducted (Wawi and Al-Sadik schools) are part of the annual
deworming in Zanzibar and are therefore regularly treated with
albendazole.
The placebo-controlled treatment group had a cure rate of
55.6% against hookworms. This finding might indicate that the
diagnostic tool used to detect hookworm eggs in this study was not
sufficiently sensitive. One reason might be that subjects with light
infections may only shed very few or sometimes no eggs, resulting
in a negative Kato-Katz test result [33,34]. To overcome this
problem in future studies it might be advisable to use an additional
diagnostic technique with higher sensitivity such as the FLOTAC
technique, which allows using a larger amount of stool, or indirect
diagnostic technique such as multiplex real-time PCR [33,35–38].
We observed a high frequency of adverse events, but these were
mostly mild, were, at times, already reported before treatment,
and also by placebo recipients [39]; and hence were not
consistently treatment related. Nevertheless, 3 and 24 hours after
the first day of treatment (administration of nitazoxanide or a
nitazoxanide-matching placebo) children treated with nitazoxa-
nide reported significantly more adverse events compared to those
who had received placebo. This increase in adverse events was not
observed after the second day of treatment (children treated with
albendazole suffered from a similar number of adverse events
episodes than children who had obtained placebo), suggesting that
the standard treatment albendazole triggers less adverse events
than nitazoxanide. Adverse events related to treatment were
resolved 24 hours after the second treatment, and the highest
number of adverse events was reported from placebo-treated
children.
In conclusion, a single oral dose of nitazoxanide cannot be
recommended for the treatment of infection with T. trichiura since
we observed low cure rate and ERR as well as significantly more
adverse events than the standard drug albendazole. Note that,
nitazoxanide is also much more expensive than the benzimid-
azoles, pyrantel pamoate, or levamisole. Moreover, also albenda-
zole showed a low efficacy against T. trichiura in our study setting
which did also not significantly improve by adding nitazoxanide
on the next treatment day. Therefore the discovery and
development of novel anthelmintic drugs, in particular against
infections with T. trichiura, has a high priority.
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Checklist S1 CONSORT Checklist.
(PDF)
Protocol S1 Trial Protocol.
(DOC)
Table S1 Effect of albendazole, nitazoxanide, sequentially
administered albendazole-nitazoxanide combination, and placebo
against soil-transmitted helminths calculated with available-case
analysis.
(DOC)
Table 3. Assessed adverse events among the four treatment arms during a randomized, placebo-controlled trial carried out on
Pemba Island, Tanzania.
Time point Adverse events: none/mild
Percentage of people with adverse events
Overall Nitazoxanide+albendazole Albendazole Nitazoxanide Placebo
Before treatment 648/28 155/9 163/8 166/6 164/5
4.1% 5.5% 4.7% 3.5% 3.0%
3 hours after first treatment 577/101 133/31* 155/16 139/34* 150/20
14.9% 18.9% 9.4% 19.7% 11.8%
24 hours after first treatment 622/56a 145/19a 160/11 153/20 164/6
8.3% 11.6% 6.4% 11.6% 3.5%
3 hours after second treatment 606/51 144/15 157/12 151/16 154/8
7.8% 9.4% 7.1% 9.6% 4.9%
24 hours after second treatment 576/51 138/12 147/12 149/12 142/15
8.1% 8.0% 7.5% 7.5% 9.6%
Adverse events were assessed at five different time points (before treatment, 3 and 24 hours after first treatment, and 3 and 24 hours after second treatment).
Nitazoxanide was given on the first day of treatment, while albendazole was given on the second day of treatment.
*statistically significant more adverse events in nitazoxanide-treated children compared to children receiving placebo.
aOne of these adverse events was classified as moderate.
doi:10.1371/journal.pntd.0001685.t003
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Table S2 Number of specific adverse events assessed at different
time points.
(DOC)
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